🇺🇸 FDA
Patent

US 8207170

Heterocyclic substituted piperazines with CXCR3 antagonist activity

granted A61PA61P1/04A61P17/06

Quick answer

US patent 8207170 (Heterocyclic substituted piperazines with CXCR3 antagonist activity) held by Pharmacopeia Drug Discovery, Inc. expires Mon Jun 21 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Pharmacopeia Drug Discovery, Inc.
Grant date
Tue Jun 26 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 21 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61P, A61P1/04, A61P17/06, A61P19/00, A61P19/02